The New Brunswick, New Jersey, company reported net income of US$4.37bn, or US$1.60 per share. Adjusted per-share earnings were US$2.06, a nickel better than expected, according to a poll by Zacks Investment Research.
READ: Johnson & Johnson, Imerys ordered to pay additional US$80mln in punitive damages in talc-cancer case
The world’s biggest maker of healthcare products, clocked revenue of US$20bn, topping analysts' projections for US$19.48bn.
Shares of Johnson & Johnson rose nearly 1% to US$133 in pre-market trade.
Johnson & Johnson expects full-year earnings in the range of US$8 to US$8.20 per share, with revenue in the range of US$81bn to US$81.8bn.
"We had a very strong quarter. We carried our momentum from 2017 into 2018, and our pharmaceutical business continued to have stellar results," Johnson & Johnson Chief Financial Officer Dominic Caruso told CNBC.
The firm’s pharma business, especially cancer drug sales in Imbruvica and Darzalex, posted US$9.84bn in revenue, a 15% year-over-year operational jump in the quarter.